Job Opportunity: Editor-in-Chief, Nature Communications

Nature Portfolio flagship Open Access journal Nature Communications is recruiting for an Editor-in-Chief to join the team
Job Opportunity: Editor-in-Chief, Nature Communications
Like

Nature Portfolio flagship Open Access journal Nature Communications is looking to appoint an Editor-in-Chief. The journal publishes high quality research across natural and social sciences and has published over 6100 papers last year.

The new Editor-in-Chief will join the senior Executive Editorial team to manage and oversee all Nature Journals and ensure Nature Portfolio is at the forefront of Open Research.

The successful candidate will display a clear vision for the future development of Nature Communications, with a particular emphasis on how the journal can meet the needs of its main customer groups. They will need to be able to operate as part of a close-knit team, and to lead the journal through changes in policies, workflows and processes.

Find out more about the role and how to apply here.

Here you will find some FAQs about recruitment at Springer Nature.

Please sign in or register for FREE

If you are a registered user on Research Communities by Springer Nature, please sign in

Subscribe to the Topic

Electrical and Electronic Engineering
Technology and Engineering > Electrical and Electronic Engineering

Related Collections

With collections, you can get published faster and increase your visibility.

Pre-clinical drug discovery

We welcome studies reporting advances in the discovery, characterization and application of compounds active on biologically or industrially relevant targets. Examples include emerging screening technologies, the development of small bioactive compounds/peptides/proteins, and the elucidation of compound structure-activity relationships, target interactions and mechanism-of-action.

Publishing Model: Open Access

Deadline: Dec 31, 2023

Biomedical applications for nanotechnologies

Overall, there are still several challenges on the path to the clinical translation of nanomedicines, and we aim to bridge this gap by inviting submissions of articles that demonstrate the translational potential of nanomedicines with promising pre-clinical data.

Publishing Model: Open Access

Deadline: Dec 31, 2023